Skip to main content

Table 5 Expression of adverse effects in instructions in FAERs

From: Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials

SOC

AEs

PRR

Vascular disorders

hypertension

6.505

Arterial thromboembolism

6.753

Deep Vein Thrombosis

3.548

Hemorrhage

2.66

Skin and subcutaneous tissue disorders

Hand-foot syndrome

11.657

Respiratory, thoracic and mediastinal disorders

pulmonary infarction

4.653

epistaxis

5.028

Renal and urinary disorders

proteinuria

37.155

Metabolism and nutrition disorders

decreased appetite

2.213

hypomagnesaemia

3.993

Blood and lymphatic system disorders

neutropenia

4.651

anaemia

4.05

thrombocytopenia

5.357

febrile neutropenia

6.758

leukopenia

4.68

lymphopenia

2.062

General disorders and administration site conditions

pyrexia

2.342

mucosal inflammation

7.727

Gastrointestinal disorders

gastrointestinal perforation

90.464

intestinal obstruction

9.696

stomatitis

4.656

rectal hemorrhage

2.439

gastrointestinal disorder

2.75

Cardiac disorders

cardiac failure

2.029

Nervous system disorders

peripheral sensory neuropathy

21.777